FDA Approves Tiratricol (Emcitate) as the First Treatment for MCT8 Deficiency

The U.S. Food and Drug Administration (FDA) has approved tiratricol (Emcitate) for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. This marks the first FDA-approved therapy for this rare genetic disorder, offering clinicians a method to lower excess circulating thyroid hormone that can strain the heart and metabolism in affected patients.